Tiba Aynechi is a Partner at Novo Ventures (US) Inc. in San Francisco, California, that she joined in 2010. She is a member of the Board of Directors of AnaptysBio Inc., Arcellx, Cianna Medical Inc. and iRhythm Technologies Inc.  

Previously, she was a board member of Thesan Pharmaceuticals Inc. Tiba has more than 10 years of combined research and banking experience in life sciences that spans various therapeutic areas and technology platforms.

Prior to joining Novo Ventures (US) Inc., Tiba was a Director with Burrill & Company where she has completed regional and cross-border M&A, licensing, and financing transactions for biotech and large pharmaceutical companies.

Tiba received her PhD from the Graduate Group in Biophysics at the University of California, San Francisco where her research involved developing computational methods for drug discovery. She has an undergraduate degree in physics from the University of California, Irvine. Tiba is also a published author of scientific articles and book chapters in the area of rational drug design.

Fund's investment verticals: biotechnology, healthcare, and life sciences with a focus on investments in products for diagnosis, control, treatment, and prevention of disease, development and application of biotechnology, instruments and medical devices, improvement of food, nutrition and health for humans and animals, and development of sustainable solutions for the environment.